Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 9, 2011, Pages 1429-1438

  Reyes Soffer, Gissette ^a   Rondon Clavo, Carlos ^a   Ginsberg, Henry N ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

ACCORD; combination therapy; dyslipidemia; fibrates; insulin resistance; metabolic syndrome; statins; type two diabetes mellitus

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLINE FENOFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; HUMAN; INSULIN RESISTANCE; KIDNEY FAILURE; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 79956137769     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.563506     Document Type: Review

References (106)

1. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
2. Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009;4:113-19
3. Mente A, Yusuf S, Islam S, et al; INTERHEART investigators. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010;55:2390-8
4. Deedwania P, Barter P, Carmena R, for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet 2006;368:919-28 (Pubitemid 44331360)
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96 (Pubitemid 39140624)
6. Collins R, Armitage J, Parish S, Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes.. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes. Lancet 2005;361:2005-16
7. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin N Am 2006;35:491-510 (Pubitemid 44339576)
8. Musunuru K, Orho-Melander M, Caulfield MP, et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009;29:1975-80
9. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol < 100 mg/dl, Am. J. Cardiol. 2006; 98 1599-1602 (Pubitemid 44827965)
10. Austin MA, Breslow JL, Hennekens CH, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21
11. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol 2007;1:583-92 (Pubitemid 350215511)
12. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009;119:931-9
13. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002;90:89-94 (Pubitemid 34775113)
14. Mora S, Szkio M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2007;192:211-17 (Pubitemid 46602300)
15. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetic and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002;105:1424-8 (Pubitemid 34263272)
16. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009;104:459-63
17. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10 (Pubitemid 47481452)
18. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14
19. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-19 (Pubitemid 26266496)
20. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Non-fasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308 (Pubitemid 47080484)
21. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Non-fasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008;300:2142-52
22. Assman G, Schulte H. The prospective cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988;116:1713-24 (Pubitemid 19015651)
23. Hopkins PN, Wu L, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. JACC 2005;45:1003-12 (Pubitemid 40432430)
24. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15 (Pubitemid 19043669)
25. Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the lipid rsearch clinics prevalence study. Am J Epidemiol 1990;131:32-47 (Pubitemid 20014697)
26. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000
27. Scriver C, Beaudet A, Sly W, Valle D. The metabolic and molecular bases of inherited disease. 8th edition. McGraw-Hill, Inc., Part 12 Lipids, New York; 2001. p. 2705-960
28. Baigent C, Keech A, Kearney PM, for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
29. Amarenco P, Goldstein LB, Messig M, et al; SPARCL Investigators. Relative and cumulative effects of lipid and blood pressure control in the stroke prevention by aggressive reduction in cholesterol levels trial. Stroke 2009;40:2486-92
30. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1-10
31. Terje RP, Anders GO, Ole F, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 1998;97:1453-60
32. Haffner SM, Alexander CM, Cook TJ, for the Scandinavian Simvastatin Survival Study Group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999;159:2661-7
33. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The care investigators. Circulation 1998;98:2513-19 (Pubitemid 29001188)
34. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9.795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8
35. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
36. Zhang YL, Hernandez-Ono A, Siri P, et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 2006;281:37603-15 (Pubitemid 46042063)
37. East C, Bilheimer DW, Grundy SM. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med 1988;109:25-32
38. Illingworth DR, Bacon S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patiens with heterozygous familial hypercholesterolemia. Circulation 1989;79:590-6 (Pubitemid 19087710)
39. Illingworth DR, O'Malley JP. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. Metabolism 1990;39:403-9 (Pubitemid 20146593)
40. Glueck CJ, Oakes N, Speirs J, et al. Gemfibrozil-Lovastatin therapy for primary hyperlipoproteinemias. Am J Cardiol 1992;70:1-9
41. Deslypere JP. Addition of fibrates to simvastatin therapy in hyperlipidaemic patients. Atherosclerosis 1992;97:S67-71
42. Da Col PG, Fonda M, Fisicaro M, et al. Tolerability and efficacy of combination therapy with Simvastatin plus Gemfibrozil in type IIb refractory familial combined hyperlipidemia. Curr Ther Res 1993;53:473-83 (Pubitemid 23242215)
43. Hutchesson ACJ, Moran A, Jones AF. Dual Bezafibrate-Simvastatin therapy for combined hyperlipidaemia. J Clin Pharm Ther 1994;19:387-9 (Pubitemid 24369411)
44. Rosenson RS, Frauenheim WA. Safety of combined pravastatin-gemfibrozil therapy. Am J Cardiol 1994;74:499-500 (Pubitemid 24269974)
45. Eliav O, Schurr D, Pfister P, et al. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995;76:76A-79A
46. Feher MD, Foxton J, Banks D, et al. Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolamia in patients with coronaty artery disease. Br Heart J 1995;74:14-17
47. Kontopoulos AG, Athyros VG, Papageorgious AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidamia and coronary artery disease. Coron Artery Dis 1996;7:843-50
48. Napoli C, Lepore S, Chiariello P, et al. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIb hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther 1997;2:17-26 (Pubitemid 27157109)
49. Ellen RLB, McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-65B (Pubitemid 28113948)
50. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138:151-5 (Pubitemid 29331136)
51. Papadakis JA, Ganotakis ES, Jagroop IA, et al. Statin + Fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237-44 (Pubitemid 29254099)
52. van Dam M, Kastelein J; Fluvastatin Collaboration Group. Efficacy and tolerability of fluvastatin in a titration dosage regimen in hyperlipidamic patients-results of a multicentre phase IV study. Clin Drug Investig 2001;21:477-84 (Pubitemid 32681919)
53. Athyros VG, Papageorgious AA, Athyrou VV, et al. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9:33-9 (Pubitemid 34311431)
54. Liamis G, Kakafika A, Bairaktari E, et al. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia. Curr Med Res Opin 2002;18:125-8 (Pubitemid 34665749)
55. Athyros VG, Papageorgious AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202 (Pubitemid 41071172)
56. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI Trial). Am J Cardiol 2005;95:462-8 (Pubitemid 40247539)
57. Winklund O, Bergman M, Bondjers G, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993;94:13-20 (Pubitemid 23021166)
58. Athyros VG, Papageorgious AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80:608-13 (Pubitemid 27386146)
59. Farnier M, Dejager S; the French Fluvastatin Study Group. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol 2000;85:53-7 (Pubitemid 30045545)
60. Vega GL, Ma PTS, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956-60 (Pubitemid 36398528)
61. Derosa G, Cicero AFG, Bertone G, et al. Comparison of Fluvastatin + Fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004;26:1599-607 (Pubitemid 39643020)
62. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2003;64:137-51
63. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-8 (Pubitemid 40247539)
64. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. Am J Cardiol 2005;45:1649-53 (Pubitemid 40704501)
65. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT-335 (Fenofibric Acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 2009;204:208-15
66. Davidson MH, Rooney MW, Drucker J, et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther 2009;31:2824-38
67. Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of ABT-335 (Fenofibric Acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009;157:195-203
68. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (Fenofibric Acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-22
69. Eli MR, James MM, Maureen TK, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. Am J Cardiovasc Drugs 2010;10:175-86
70. Jones PH, Cusi K, Davidson MH, et al. Efficacy and safety of fenofibric acid co-administerd with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs 2010;10:73-84
71. Leitersdorf E, Muratti EN, Osnat E, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med 1994;96:401-7
72. Feussner G, Eichinger M, Ziegler R. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin Investigator 1992;70:1027-35
73. Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80:78-81 (Pubitemid 27274585)
74. Vakkilainen J, Steiner G, Ansquer JC, et al. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care 2002;25:627-8
75. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90 (Pubitemid 39577514)
76. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51 (Pubitemid 34595097)
77. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokineticinteraction with fenofibrate in humans. J Clin Pharmacol 2004;44:1054-62 (Pubitemid 39096820)
78. Shek A, Ferrill MJ. Statin-Fibrate combination therapy. Ann Pharmacother 2001;35:908-17 (Pubitemid 32678717)
79. Illiadis EA, Rosenson RS. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 1999;22:25-8 (Pubitemid 29046993)
80. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/ NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:568-73
81. Keech A, Simes RJ, Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet 2005;366:1849-61
82. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardio 2004;93:848-53 (Pubitemid 38429595)
83. Ansquer J-C, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-13 (Pubitemid 351697561)
84. Davis TME, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2010. [Epub ahead of print]
85. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
86. Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42
87. Buse JB, Bigger JT, et al; Accord Study Group. Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i
88. Gerstein HC, Miller ME, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59 (Pubitemid 351831356)
89. Cushman WC, Evans GW, et al; Accord Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
90. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death. Arch Intern Med 2004;164:1422-6
91. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 yr cardiovascular mortality for men screened in the multiple tisk factor intervention trial. Diabetes Care 1993;16:434-44 (Pubitemid 23046633)
92. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34 (Pubitemid 28350165)
93. Shepherd J, Barter P, Carmena R, et al; for the Treating to New Targets Investigators. Effect of lowering LDL cholesterol substantially below currently recommended levles in patients with coronary heart disease and diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6 (Pubitemid 44125913)
94. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease. Arch Intern Med 2002;162:2597-604
95. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8 (Pubitemid 28112428)
96. Frick MH, Elo MO, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. NE J Med 1987;317:1237-45 (Pubitemid 17147964)
97. Manninen V, Elo MO, Frick MH, et al. Alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 1988;260:641-51
98. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki heart study. Circulation 1995;92:1779-85
99. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesteroal intervention trial study group. N Engl J Med 1999;341:410-18 (Pubitemid 29362514)
100. Robins SJ, Rubins HB, Faas FH, et al. Insulin resistance and cardiovascular events with low HDL cholesterol. Diabetes Care 2003;26:1513-17
101. The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000;102:21-7
102. Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005;165:1154-60 (Pubitemid 40720740)
103. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardio 2005;45:185-97 (Pubitemid 40094724)
104. Saha SA, Kizhakepunnur LG, Bahekar H, Arora RR. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53 (Pubitemid 350001283)
105. Jun M, Foote C, Neal B, et al. Effects of fibrates on cardiovascular outcomes:a ystematic review and meta-analysis. Lancet 2010;375:1875-84
106. Sacks FM, Carey VJ, Fruchart J-C. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4